These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12692609)

  • 41. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
    Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
    Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study.
    Lewalle P; Triffet A; Delforge A; Crombez P; Selleslag D; De Muynck H; Bron D; Martiat P
    Bone Marrow Transplant; 2003 Jan; 31(1):39-44. PubMed ID: 12621505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.
    El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Calmels B; Oudin C; Lemarie C; Granata A; Devillier R; Vey N; Bouabdallah R; Chabannon C; Blaise D
    Exp Hematol; 2013 Jan; 41(1):17-27. PubMed ID: 23022128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
    Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
    Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
    Mutis T; Aarts-Riemens T; Verdonck LF
    Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.
    Anderlini P; Acholonu SA; Okoroji GJ; Andersson BS; Couriel DR; De Lima MJ; Donato ML; Khouri IF; Giralt SA; Ueno NT; Champlin RE
    Bone Marrow Transplant; 2004 Sep; 34(6):511-4. PubMed ID: 15273710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
    Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
    J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.
    Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL
    Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Drobyski WR; Roth MS; Thibodeau SN; Gottschall JL
    Bone Marrow Transplant; 1992 Sep; 10(3):301-4. PubMed ID: 1422483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.
    Russell NH; Byrne JL; Faulkner RD; Gilyead M; Das-Gupta EP; Haynes AP
    Bone Marrow Transplant; 2005 Sep; 36(5):437-41. PubMed ID: 15980879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.
    Amrolia PJ; Rao K; Slater O; Ramsay A; Veys PA; Webb DK
    Bone Marrow Transplant; 2001 Sep; 28(6):623-5. PubMed ID: 11607779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
    Simula MP; Marktel S; Fozza C; Kaeda J; Szydlo RM; Nadal E; Bua M; Rahemtulla A; Kanfer E; Marin D; Olavarria E; Goldman JM; Apperley JF; Dazzi F
    Leukemia; 2007 May; 21(5):943-8. PubMed ID: 17361226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients.
    Russell LA; Jacobsen N; Heilmann C; Simonsen AC; Christensen LD; Vindelov LL
    Bone Marrow Transplant; 1996 Aug; 18(2):411-4. PubMed ID: 8864454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.